Akers Biosciences Inc. (AKER)

[$treet $inatra]

AKER bouncing after supposedly good scam results?

Akers Biosciences Inc. and partner Premas Biotech said Thursday they saw positive proof of concept results from animal studies conducted during a four- week test of its SARS-CoV-2 vaccine candidate in mice.

The companies said the test had two primary endpoints, safety and immune response, both of which were met. The candidate was well tolerated and safe in mice that received the intramuscular injection, and a robust immune response also was observed.
The study consisted of 50 mice, divided into 10 cohorts dosed with 5, 10 and 20 micrograms of the PRAK-03202 vaccine candidate. The vaccine candidate was generally well tolerated and safe at all doses, with no adverse events reported.

Premas will seek to further characterize the immune response in the near term, while pursuing additional safety studies and later stage animal testing with the goal of an investigational new drug submission to follow in the U.S. Premas continues to be engaged formally with authorities and the Drug Controller in India. Both Akers and Premas also are in discussions with regulators in the U.S.